Lastly, CELMoDs, which are an evolving treatment strategy for myeloma, build upon the long-standing success of IMiDs by using a slightly different molecular structure that allows for more enhanced interaction with traditional IMiD substrates such as cereblon [154]. Here, CRBN is linked to plasma cell myeloma.